Loading...
•
Mar 31, 2023
Zimmer Biomet Q1 2023 Earnings Report
Reported strong Q1 performance, outperforming internal growth expectations with net sales increasing by 10.1% and adjusted diluted earnings per share at $1.89.
Key Takeaways
Zimmer Biomet announced first quarter net sales of $1.831 billion, a 10.1% increase year-over-year, and an adjusted diluted earnings per share of $1.89. The company has raised and tightened its 2023 financial guidance.
First quarter net sales of $1.831 billion increased 10.1% and 13.2% on a constant currency basis.
First quarter diluted earnings per share were $1.11; adjusted diluted earnings per share were $1.89.
Company raises and tightens 2023 financial guidance.
Launch of the Persona® OsseoTi® Keel Tibia for cementless knee replacement.
Zimmer Biomet
Zimmer Biomet
Zimmer Biomet Revenue by Segment
Revenue by Segment
Knees Revenue
CapyFin.comHips Revenue
CapyFin.comS.E.T. Revenue
CapyFin.comTech/Data/Surgical Revenue
CapyFin.com Forward Guidance
The Company is providing the following updated full-year 2023 financial guidance:
Positive Outlook
- 2023 Reported Revenue Change: 5.0% - 6.0%
- Foreign Currency Exchange Impact: (1.0)%
- Adjusted Diluted EPS: $7.40 - $7.50
Revenue & Expenses
Visualization of income flow from segment revenue to net income